Precision Medicine Seminar Series with Dr. Bo Rueda, Ph.D.
Stem-like properties are transferred between ovarian tumor cells via extracellular vesicles facilitating epigenetic changes promoting drug resistance.
Event Details
Date
Monday, July 21, 2025
Time
12-1 p.m.
Location
Description
Surviving post-treatment ovarian cancer stem cells (CSCs) serve as the foundation for recurrent drug-resistant disease. Equally challenging to patient outcomes is that non-CSCs can acquire CSC phenotypic properties under the stress of aggressive treatment strategies. The mechanisms by which this phenotypic change occurs in the non-stem tumor cell population are of increasing interest. Utilizing multiple preclinical OvCa models, we provide evidence that small extracellular vesicles (EVs) from CSC
Cost
Free
Contact
Accessibility
We value inclusion and access for all participants and are pleased to provide reasonable accommodations for this event. Please call 608-263-7866 (voice only) or email info@chgpm.wisc.edu to make a disability-related accommodation request. Requests should be made by Monday, July 7, 2025, though reasonable effort will be made to support late accommodation requests.